Tech Company Financing Transactions
Trubion Pharmaceuticals Funding Round
Trubion Pharmaceuticals, based in Seattle, secured $32 million from Prospect Venture Partners, Venrock and Arch Venture Partners.
Transaction Overview
Company Name
Announced On
7/14/2004
Transaction Type
Venture Equity
Amount
$32,000,000
Round
Series B
Investors
Prospect Venture Partners (Lead Investor) (David Schnell)
Venrock (Lead Investor) (Anders Hove)
Proceeds Purpose
Trubion plans to use the proceeds from this financing to advance its lead products through human clinical trials while continuing to build a rich pipeline of therapeutic product candidates addressing both precedented and novel targets.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
2401 4th Ave 1050
Seattle, WA 98121
USA
Seattle, WA 98121
USA
Phone
Website
Email Address
Overview
Trubion Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines to treat inflammatory disease and cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steven Gillis
Chief Financial Officer
Michelle Burris
Chief Medical Officer
Scott Stromatt
VP - General Counsel
Kathleen Deeley
VP - R & D
Kendall Mohler
Browse more venture capital transactions:
Prev: 7/14/2004: Mahi Networks venture capital transaction
Next: 7/14/2004: SkinMedica venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs